While shares of Teva (TEVA 2.00%) have risen a modest 9% year to date, the company is trading at low valuation compared to many of its peers in the pharmaceutical industry. Its forward P/E is significantly lower than major players like Merck, Pfizer, and Mylan, but what specific topics should investors focus on when analyzing this investment today? In the following video, analyst Max Macaluso discusses three key issues on his radar: Teva's standing in the multiple sclerosis market and competition from companies including Biogen (BIIB 0.75%), rumors around a possible merger, and its leadership.
Teva Stock: 3 Key Things to Know
By Max Macaluso – Nov 29, 2013 at 8:00AM
NYSE: TEVA
Teva Pharmaceutical Industries
Market Cap
$27B
Today's Change
(-2.00%) $0.49
Current Price
$23.97
Price as of November 7, 2025 at 4:00 PM ET
What key issues should investors look at when analyzing Teva's stock?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo